Nanosonics Limited 2024 Full-Year Performance Report

Nanosonics Limited (NAN:ASX), a leader in infection prevention solutions, reported a robust turnaround in its 2024 full-year performance during the recent earnings call. The company experienced a significant second-half revenue increase of 14% to $90.4 million, attributing the growth to a 24% rise in capital unit sales and a 20% increase in capital revenue.

Key Takeaways

• Second-half revenue rose to $90.4 million, a 14% increase.
• Capital unit sales and capital revenue increased by 24% and 20%, respectively.
• Expected revenue growth of 8% to 12% in the current financial year.
• North America market penetration for the trophon product reached 50%.
• The company has $130 million in cash and equivalent resources.
• Trophon business reported a pre-tax profit of $40.4 million.
• Identified upgrade opportunity for 9,000 older trophon devices in North America.
• Overall revenue for the year was $170 million, a 2% year-over-year increase.
• Gross profit margin was 77.9%.
• Operating expenses grew by 10%, with a projected 6-10% increase for FY ’25.
• Free cash flow was reported at $20.4 million.

Company Outlook

• Targeting 8% to 12% revenue growth for FY ’25.
• Plans to expand product portfolio through mergers and acquisitions.
• Positive operating leverage and improved operating margin expected for the trophon business in FY ’25.
• Aiming to increase new unit sales to 3,000 per year globally.

Bearish Highlights

• Profit before tax decreased by $8.6 million from the previous year, largely due to hospital capital budget constraints.
• Expected increase in operating expenses for FY ’25, though at a slower pace than FY ’24.

Bullish Highlights

• Significant growth opportunities identified in North America for trophon product upgrades.
• Strong sales of consumables driven by increased ultrasound procedural volumes.
• Growing service contracts are becoming a significant contributor to revenue and cash flow.

Misses

• Only 620 trophon device upgrades were sold in the first half, affected by hospital budget constraints, though a 71% increase in upgrade sales occurred in the second half in North America.

Q&A Highlights

• CEO Michael Kavanagh noted that normal FDA questions regarding the CORIS device would not affect approval timelines.
• Expressed optimism regarding growth in Europe, particularly in the UK and with Ecolab.
• Confidence in progress in Japan and China markets, despite no specific revenue projections provided.

Strategy and Technology

Nanosonics’ strategic focus on research and development has led to the development of the CORIS product, which aims to address the critical need for cleaning flexible endoscopes. With more than 60 million endoscope procedures performed annually, the company sees a significant market opportunity. The filing of the FDA De Novo regulatory submission for CORIS marks a critical milestone, and the company is working to address queries from the FDA.

The company is also implementing a new ERP system, with a $1 million investment expected to complete in FY ’25 and support growth and operational efficiency.

Overall, Nanosonics’ strategic focus on product upgrades, market expansion, and innovation positions it favorably for the upcoming financial year, with a strong financial foundation and strategic direction supporting continued success in the infection prevention market.